Tardive dyskinesia in children treated with atypical antipsychotic medications

Movement Disorders

Volumn 22, Issue 12, 2007, Pages 1777-1782

  Wonodi, Ikwunga ^a,b   Reeves, Gloria ^a   Carmichael, Dana ^a   Verovsky, Ilene ^a   Avila, Matthew T ^a   Elliott, Amie ^a   Hong, L Elliot ^a   Adami, Helene M ^a   Thaker, Gunvant K ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Atypical antipsychotics; Children; Tardive dyskinesia

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; HALOPERIDOL; LOXAPINE; MOLINDONE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE; ZIPRASIDONE;

ADOLESCENT; AFRICAN AMERICAN; ARTICLE; ASIAN; CHILD; CHILD PSYCHIATRY; DRUG SAFETY; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FEMALE; FISHER EXACT TEST; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ADOLESCENT; AFRICAN AMERICANS; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DYSKINESIA, DRUG-INDUCED; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX;

EID: 35348944454     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21618     Document Type: Article

References (39)

1. Coyle JT. Psychotropic drug use in very young children. JAMA 2000;283:1059-1060.
2. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000;283:1025-1030.
3. Zito JM, Safer DJ, dosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003;157:17-25.
4. Kalb C. Drugged-out toddlers. A new study documents an alarming increase in behavior-altering medication for preschoolers. Newsweek 2000 Mar 6;135:53.
5. Martin A, Leslie D. Trends in psychotropic medication costs for children and adolescents, 1997-2000. Arch Pediatr Adolesc Med 2003;157:997-1004.
6. Shatin D, Drinkard CR. Ambulatory use of psychotropics by employer-insured children and adolescents in a national managed care organization. Ambul Pediatr 2002;2:111-119.
7. Park A. Psychotropic Drugs and Children. Time Online; Web Exclusive Health, The Daily Rx, Monday, Aug. 1, 2005.
8. Findling RL, McNamara NK. Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry 2004;65 (Suppl 6):30-44.
9. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006;63:679-685.
10. Pappadopulos E, Macintyre Ii JC, Crismon ML, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY), Part II. J Am Acad Child Adolesc Psychiatry 2003;42:145-161.
11. Connor DF, Fletcher KE, Wood JS. Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 2001;62:967-974.
12. Malone RP, Sheikh R, Zito JM. Novel antipsychotic medications in the treatment of children and adolescents. Psychopharmacology 1999;50:171-174.
13. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997;36:835-843.
14. Greenhill LL, Vitiello B, Abikoff H, et al. Developing methodologies for monitoring long-term safety of psychotropic medications in children: report on the NIMH conference, September 25, 2000. J Am Acad Child Adolesc Psychiatry 2003;42:651-655.
15. Safer DJ. Changing patterns of psychotropic medications prescribed by child psychiatrists in the 1990s. J Child Adolesc Psychopharmacol 1997;7:267-274.
16. Patel NC, Crismon ML, Hoagwood K, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005;44:548-556.
17. Worrel JA, Marken PA, Beckman SE, Ruehter VL. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 2000;57:238-255.
18. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414-425.
19. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004;29:133-145.
20. Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B. Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol Bull 1984;20:39-40.
21. Gillberg C. Typical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 2000;9 (Suppl 1):I2-I8.
22. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329:162-167.
23. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996;53:1090-1097.
24. Remschmidt HE, Schulz E, Martin M, Warnke A, Trott GE. Childhood-onset schizophrenia: history of the concept and recent studies. Schizophr Bull 1994;20:727-745.
25. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006;45:771-791.
26. Cassady SL, Thaker GK, Summerfelt A, Tamminga CA. The Maryland Psychatric Research Center scale for the characterization of involuntary movements. Psychiatry Res 1997;70:21-37.
27. Guy W. ECDEU assessment manual for psychopharmacology. US Department of Health, Education and Welfare NIMH 1976;76:338.
28. Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 2000;61 (Suppl 4):21-26.
29. King B, Zwi K, Nunn K, Longworth J, Dossetor D. Use of risperidone in a paediatric population: an observational study. J Paediatr Child Health 2003;39:523-527.
30. Richardson MA, Haugland G, Craig TJ. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Am J Psychiatry 1991;148:1322-1328.
31. Magulac M, Landsverk J, Golshan S, Jeste DV. Abnormal involuntary movements in neuroleptic-naive children and adolescents. Can J Psychiatry 1999;44:368-373.
32. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993;54:133-139.
33. Glazer WM, Morgenstern H, Doucette J. Race and tardive dyskinesia among outpatients at a CMHC. Hosp Community Psychiatry 1994;45:38-42.
34. Swartz JR, Burgoyne K, Smith M, Gadasally R, Ananth J, Ananth K. Tardive dyskinesia and ethnicity: review of the literature. Ann Clin Psychiatry 1997;9:53-59.
35. Wonodi I, Adami HM, Cassady SL, Sherr JD, Avila MT, Thaker GK. Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center. J Clin Psychopharmacol 2004;24:592-598.
36. Largo RH, Fischer JE, Rousson V. Neuromotor development from kindergarten age to adolescence: developmental course and variability. Swiss Med Wkly 2003;133:193-199.
37. Denckla MB. Why assess motor functions "early and often?" Ment Retard Dev Disabil Res Rev 2005;11:3.
38. Gualtieri CT, Patterson DR. Neuroleptic-induced tics in two hyperactive children. Am J Psychiatry 1986;143:1176-1177.
39. Casat CD, Wilson DC, III. Tics with combined thioridazine-methylphenidate therapy: case report. J Clin Psychiatry 1986;47:44-45.